Alliance Pharma PLC Notification of Half Year Results (8452I)
August 10 2023 - 2:00AM
UK Regulatory
TIDMAPH
RNS Number : 8452I
Alliance Pharma PLC
10 August 2023
For immediate release 10 August 2023
ALLIANCE PHARMA PLC
("Alliance", "Company" or the "Group")
Notification of Half Year Results
Alliance Pharma plc (AIM: APH), the international consumer
healthcare company, announces a change of date for the publication
of its results for the six months ended 30 June 2023. The interim
results will be released on Tuesday 26 September 2023.
A meeting for analysts will be held at 9:30am on 26 September
2023 at Buchanan, 107 Cheapside, London EC2V 6DN. To register for
the meeting, analysts should contact Buchanan at
alliancepharma@buchanan.uk.com .
A live webcast of the analyst meeting will be accessible via the
following link:
https://stream.buchanan.uk.com/broadcast/64d35bfa8964824b00aaa7a0
Following the meeting, a replay of the webcast will be made
available at the investor section of Alliance's website,
https://www.alliancepharmaceuticals.com/investors/ ,
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations
& Corporate Communications + 44 (0)1249 705168
ir@allianceph.com
+ 44 (0)20 7466
Buchanan 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited (Nominated Adviser + 44 (0)20 7260
and Joint Broker) 1000
Freddie Barnfield / Duncan Monteith / Sher
Shah
+ 44 (0)20 7597
Investec Bank plc (Joint Broker) 5970
Patrick Robb / Maria Gomez de Olea
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare
company. Our purpose is to empower people to make a positive
difference to their health and wellbeing by making our trusted and
proven brands available around the world.
We deliver organic growth through investing in our priority
brands and channels, in related innovation, and through selective
geographic expansion to increase the reach of our brands.
Periodically, we may look to enhance our organic growth through
selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics we
remain asset-light and focused on maximising the value we can
bring, both to our stakeholders and to our brands.
For more information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSSFFIUEDSEDA
(END) Dow Jones Newswires
August 10, 2023 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024